MitoQ trial targets MS fatigue – a new hope for tired patients?
NCT ID NCT04267926
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether MitoQ, a dietary supplement, can reduce fatigue in people with multiple sclerosis. 45 participants took either 20 mg, 40 mg, or a placebo daily for 12 weeks. Researchers measured changes in fatigue using a standard survey. The goal is to find a safe, simple way to improve daily energy for MS patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- MitoQ (mitoquinone)
- What this could lead to
- If it works, this could offer a new option to help manage fatigue in people with multiple sclerosis.
- What could go wrong
- This is an early-phase trial with only 45 participants, so results may not apply to everyone. Fatigue is subjective, and the placebo effect could be strong.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FATIGUE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
VA Portland Health Care System, Portland, OR
Portland, Oregon, 97207-2964, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we decode the different types of pain in multiple sclerosis?
- Can a blood pressure pill slow MS disability?
- Hidden MS progression: can brain scans and blood tests predict it?
- Can Brain-Training apps fix sleep in MS?
- Can an Iron-Based dye reveal hidden inflammation in progressive MS?
- Strumming for the brain: could ukulele lessons sharpen minds in MS?